IRIS
BERGANTINI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.603
NA - Nord America 12.586
AS - Asia 6.758
SA - Sud America 1.116
Continente sconosciuto - Info sul continente non disponibili 831
AF - Africa 422
OC - Oceania 28
AN - Antartide 1
Totale 35.345
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.260
IT - Italia 4.233
RU - Federazione Russa 2.977
SG - Singapore 2.242
CN - Cina 1.514
GB - Regno Unito 1.507
IE - Irlanda 1.504
BR - Brasile 919
VN - Vietnam 881
DE - Germania 769
HK - Hong Kong 706
SE - Svezia 657
FR - Francia 585
FI - Finlandia 470
IN - India 329
ZA - Sudafrica 215
KR - Corea 214
BD - Bangladesh 212
NL - Olanda 201
CA - Canada 176
ES - Italia 143
UA - Ucraina 136
JP - Giappone 107
PL - Polonia 88
IQ - Iraq 87
MX - Messico 83
TR - Turchia 72
CZ - Repubblica Ceca 71
CI - Costa d'Avorio 57
AR - Argentina 55
AT - Austria 52
PK - Pakistan 42
NG - Nigeria 40
ID - Indonesia 38
IR - Iran 38
CH - Svizzera 33
SA - Arabia Saudita 31
BE - Belgio 30
EC - Ecuador 30
KE - Kenya 29
MA - Marocco 29
UZ - Uzbekistan 29
VE - Venezuela 29
PH - Filippine 28
AE - Emirati Arabi Uniti 25
AU - Australia 23
CL - Cile 20
CO - Colombia 20
LT - Lituania 18
MY - Malesia 18
PE - Perù 18
AZ - Azerbaigian 15
EG - Egitto 15
PT - Portogallo 15
JO - Giordania 14
BG - Bulgaria 13
IL - Israele 13
KZ - Kazakistan 13
RO - Romania 13
JM - Giamaica 12
HU - Ungheria 11
PY - Paraguay 11
DZ - Algeria 10
EE - Estonia 10
LB - Libano 10
LV - Lettonia 10
PA - Panama 10
TN - Tunisia 10
NP - Nepal 9
DK - Danimarca 8
GE - Georgia 8
GR - Grecia 8
OM - Oman 8
TT - Trinidad e Tobago 8
BO - Bolivia 7
CR - Costa Rica 7
KG - Kirghizistan 7
BY - Bielorussia 6
CY - Cipro 6
EU - Europa 6
LK - Sri Lanka 6
TW - Taiwan 6
AL - Albania 5
GT - Guatemala 5
HR - Croazia 5
MK - Macedonia 5
NO - Norvegia 5
QA - Qatar 5
SN - Senegal 5
UY - Uruguay 5
DO - Repubblica Dominicana 4
ET - Etiopia 4
LA - Repubblica Popolare Democratica del Laos 4
PS - Palestinian Territory 4
SV - El Salvador 4
AM - Armenia 3
HN - Honduras 3
NI - Nicaragua 3
PR - Porto Rico 3
RS - Serbia 3
Totale 34.470
Salva come PNG Salva come JPEG
Città #
Dallas 2.249
Dublin 1.477
Singapore 1.376
Southend 1.187
Ashburn 1.025
San Jose 924
Moscow 912
Santa Clara 844
Milan 815
Hong Kong 648
Chandler 624
Fairfield 618
Siena 478
Beijing 422
Council Bluffs 403
Los Angeles 374
Munich 348
Lastra a Signa 340
Helsinki 328
Hefei 323
New York 296
Rome 292
Ho Chi Minh City 254
Houston 249
Florence 248
Seattle 232
Woodbridge 232
Wilmington 227
Hanoi 210
Seoul 205
Johannesburg 199
Lauterbourg 197
Princeton 187
Cambridge 180
The Dalles 134
Ann Arbor 126
Chicago 102
São Paulo 99
Columbus 90
Shanghai 87
Tokyo 81
Jacksonville 78
Buffalo 77
Orem 74
Warsaw 74
Bengaluru 73
Frankfurt am Main 68
Redondo Beach 68
London 65
Dong Ket 64
Fremont 64
Turku 64
Nuremberg 63
San Mateo 60
Lappeenranta 59
Málaga 59
Abidjan 57
Boardman 56
San Diego 54
Düsseldorf 52
Chennai 51
Figino 51
Turin 50
Da Nang 49
Portsmouth 49
Dearborn 47
Montreal 45
Boston 43
Brooklyn 43
Toronto 43
Brno 40
Naples 40
Phoenix 40
Atlanta 37
Denver 37
Haiphong 37
Stockholm 37
Washington 37
Amsterdam 35
Baghdad 33
Brescia 33
Abuja 32
Poplar 32
Manchester 31
Mumbai 28
Bologna 27
San Francisco 27
Newark 26
Rio de Janeiro 26
Tashkent 26
Vienna 26
Mexico City 25
Paris 25
Gavirate 24
Dhaka 23
Miami 23
Olomouc 23
Padova 23
Salt Lake City 23
Zurich 23
Totale 22.241
Salva come PNG Salva come JPEG
Nome #
A first update on mapping the human genetic architecture of COVID-19 600
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 591
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 508
Genetic mechanisms of critical illness in COVID-19 450
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 437
An explainable model of host genetic interactions linked to COVID-19 severity 384
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 382
Pathogen-sugar interactions revealed by universal saturation transfer analysis 371
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 366
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 356
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 355
Peripheral biomarkers' panel for severe COVID-19 patients 323
null 320
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 318
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 312
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 308
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 305
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 304
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 302
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 289
Immune modulatory effects of novel monoclonal antibodies target therapies in severe eosinophilic asthma patients 286
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 282
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 279
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 274
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 267
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 267
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 262
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 259
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 258
Prognostic bioindicators in severe COVID-19 patients 257
Serial KL-6 measurements in COVID-19 patients 252
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 251
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 248
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 247
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 245
Serum amyloid A in patients with idiopathic pulmonary fibrosis 244
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 244
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 242
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 239
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 237
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 234
NK and NKT-like cells in granulomatous and fibrotic lung diseases 230
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 230
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 230
Altered serum concentrations of IL-8, IL-32 and IL-10 in patients with lung impairment 6 months after COVID-19 229
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 229
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 228
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 227
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 226
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 226
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 226
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 223
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 219
Whole-genome sequencing reveals host factors underlying critical COVID-19 216
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 216
Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence 214
WES profiling of COVID-19 214
Serum amyloid A: A potential biomarker of lung disorders 209
Multi-Omics Integrative Approach of Extracellular Vesicles: A Future Challenging Milestone 207
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 205
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 204
Clinical and molecular characterization of COVID-19 hospitalized patients 204
Alteration of Immune-checkpoint after specific stimulation with CMV antigens in pre-LTx patients 204
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 202
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 202
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 200
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 200
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 198
Oxygen Therapy during Exercise in Patients with Interstitial Lung Diseases 197
Effects of rituximab therapy on B cell differentiation and depletion 196
Brain neuronal and glial damage during acute COVID-19 infection in absence of clinical neurological manifestations 194
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 191
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 187
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 187
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 187
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy 187
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 186
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 186
Characterization of NKG2-A/-C, Kir and CD57 on NK Cells Stimulated with pp65 and IE-1 Antigens in Patients Awaiting Lung Transplant 186
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 185
Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study 184
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 183
The Effects of Interstitial Lung Diseases on Alveolar Extracellular Vesicles Profile: A Multicenter Study 182
A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists 182
Neutrophil-to-lymphocyte ratio in bronchoalveolar lavage from IPF patients: a novel prognostic biomarker? 181
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 181
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 181
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 181
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 177
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a new protocol for investigating the mechanisms of idiopathic pulmonary fibrosis 177
Markers of Bronchiolitis Obliterans Syndrome after Lung Transplant: Between Old Knowledge and Future Perspective 172
Immunologic responses to antifibrotic treatment in IPF patients 169
The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis 167
Exploring the interaction between fractional exhaled nitric oxide and biologic treatment in severe asthma: a systematic review 166
Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis 165
Cytomegalovirus Infection Is Associated with Development of Chronic Lung Allograft Dysfunction 163
Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis 163
Prevalence of myositis specific and associated antibodies in a cohort of patients affected by idiopathic NSIP and no hint of inflammatory myopathies 162
Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor 162
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers 162
Totale 24.502
Salva come PNG Salva come JPEG
Categoria #
all - tutte 120.943
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 120.943
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.131 0 268 201 159 113 100 95 104 101 295 262 433
2022/20232.707 175 294 334 266 155 479 283 236 183 117 111 74
2023/20243.095 119 95 316 163 158 661 869 147 43 103 119 302
2024/20256.894 603 268 757 395 788 424 381 419 535 350 627 1.347
2025/202616.210 1.057 1.926 1.751 1.859 3.101 584 2.028 485 607 1.057 602 1.153
2026/2027906 688 218 0 0 0 0 0 0 0 0 0 0
Totale 35.345